阿尔克梅斯(纳斯达克：ALKS)股价突破200日移动均线26.61美元

Alkermes plc (NASDAQ:ALKS – Get Rating) shares passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $26.61 and traded as high as $30.58. Alkermes shares last traded at $30.53, with a volume of 50,909 shares changing hands.

A number of research analysts have weighed in on the stock. HC Wainwright lifted their price target on shares of Alkermes from $30.00 to $32.00 in a research note on Thursday, April 28th. Stifel Nicolaus lifted their price target on shares of Alkermes from $24.00 to $27.00 in a research note on Wednesday, April 27th. Mizuho lifted their price target on shares of Alkermes from $35.00 to $36.00 in a research note on Thursday, April 28th. Citigroup lifted their price target on shares of Alkermes from $22.00 to $26.00 and gave the company a "neutral" rating in a research note on Tuesday, March 22nd. Finally, The Goldman Sachs Group assumed coverage on shares of Alkermes in a research note on Wednesday, April 20th. They issued a "buy" rating and a $35.00 price target on the stock. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and an average price target of $30.67.

Get

Alkermes

alerts:

The company has a quick ratio of 1.86, a current ratio of 2.19 and a debt-to-equity ratio of 0.27. The stock's fifty day moving average price is $28.85 and its 200-day moving average price is $26.64.

Alkermes (NASDAQ:ALKS – Get Rating) last posted its quarterly earnings data on Wednesday, April 27th. The company reported $0.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.15. The company had revenue of $278.55 million for the quarter, compared to the consensus estimate of $256.02 million. Alkermes had a negative net margin of 5.13% and a positive return on equity of 3.87%. The firm's revenue was up 10.8% compared to the same quarter last year. During the same period last year, the company earned $0.01 earnings per share. Sell-side analysts predict that Alkermes plc will post -0.6 EPS for the current fiscal year.

In related news, CEO Richard F. Pops sold 93,747 shares of the business's stock in a transaction on Friday, May 6th. The shares were sold at an average price of $27.85, for a total transaction of $2,610,853.95. Following the transaction, the chief executive officer now directly owns 968,299 shares in the company, valued at $26,967,127.15. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Michael J. Landine sold 25,000 shares of the company's stock in a transaction on Tuesday, May 3rd. The shares were sold at an average price of $28.62, for a total transaction of $715,500.00. Following the completion of the transaction, the senior vice president now owns 232,306 shares in the company, valued at $6,648,597.72. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 216,220 shares of company stock worth $6,170,540. 4.76% of the stock is owned by corporate insiders.

Several large investors have recently added to or reduced their stakes in the business. BlackRock Inc. increased its holdings in shares of Alkermes by 5.8% in the first quarter. BlackRock Inc. now owns 15,080,046 shares of the company's stock valued at $396,756,000 after purchasing an additional 827,759 shares during the last quarter. Sarissa Capital Management LP boosted its position in shares of Alkermes by 6.3% in the fourth quarter. Sarissa Capital Management LP now owns 14,040,000 shares of the company's stock valued at $326,570,000 after acquiring an additional 827,000 shares during the period. State Street Corp boosted its position in shares of Alkermes by 1.5% in the first quarter. State Street Corp now owns 5,779,899 shares of the company's stock valued at $152,069,000 after acquiring an additional 85,459 shares during the period. Renaissance Technologies LLC boosted its position in shares of Alkermes by 1.2% in the first quarter. Renaissance Technologies LLC now owns 4,868,013 shares of the company's stock valued at $128,077,000 after acquiring an additional 57,068 shares during the period. Finally, Geode Capital Management LLC boosted its position in shares of Alkermes by 2.2% in the fourth quarter. Geode Capital Management LLC now owns 2,871,803 shares of the company's stock valued at $66,798,000 after acquiring an additional 61,474 shares during the period. Hedge funds and other institutional investors own 98.93% of the company's stock.

Alkermes Company Profile (NASDAQ:ALKS)

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases.

Read More

• Get a free copy of the StockNews.com research report on Alkermes (ALKS)
• 3 Home Improvement Stocks That Can Renovate Your Portfolio
• Looking to Dump These 3 Possible Delisted Chinese Stocks? Let's Take a Look.
• Get Defensive With These Three Upgrades
• Vera Bradley Stock Getting Cheap
• 3 Education Stocks to Enroll in This Summer

Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.